CoChat

Embryonic spinocerebellar ataxia type 37-associated AUUUC repeat RNA causes neurodevelopmental defects

Open access

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; none of the 105 sources its claims cite is checked for support yet.

Abstract

Onset of many neurodegenerative and neuromuscular diseases usually starts in adulthood; however, recent advances point towards neurodevelopmental changes as drivers of late neurodegeneration. How early neuropathological features occur under these conditions remains unclear, but this knowledge would be critical for timely therapeutic intervention. Here, we provide evidence that neurodevelopmental axonal defects initiate a motor phenotype in a zebrafish model of spinocerebellar ataxia type 37 (SCA37), a degenerative hereditary disease caused by an ATTTC repeat in the DAB1 gene. We investigated neuronal defects triggered by the embryonic AUUUC repeat RNA from the DAB1 gene and their effects later in life by transiently expressing this RNA in embryos and analyzing innervation and motor function. We found abnormalities in motor neuron axonal outgrowth and muscle innervation. We also discovered disrupted embryonic motor activity, and reduced locomotor distance and velocity in late adult zebrafish, demonstrating motor impairment. Moreover, we showed that protein expression of the splicing regulator NOVA2 rescues axonal defects, indicating dysfunction of NOVA2-regulated neurodevelopmental processes. Overall, our results establish embryonic expression of the AUUUC repeat RNA as a driver of axonal and synaptic abnormalities, interfering with neuronal circuits and culminating in adult motor dysfunction.

Overview

CoChat Summary

TL;DR

Transient embryonic expression of the SCA37-associated (AUUUC)58 repeat RNA in zebrafish causes axonal and neuromuscular developmental defects and later adult motor impairment. NOVA2 co-expression partially rescues the axonal phenotype, implicating NOVA2 loss-of-function in SCA37.

Key findings

  • Pathogenic (AUUUC)58 RNA microinjection increased 24 hpf lethality/morphological defects (77±21% vs 33±12% for non-pathogenic (AUUUU)7 and 25±13% for vehicle; P<0.0001), reduced survival (25% vs 55%/56%) and hatching (37% vs 74%/78%) by 96 hpf (P<0.0001).
  • It shortened primary motor neuron axons at 24 hpf (27±8 µm vs 43±12 µm for (AUUUU)7, P=0.0003; vs 40±11 µm for vehicle, P=0.004), reduced dorsal/ventral AChR distribution and AChR cluster area, and decreased α-BTX intensity at 72 hpf (1475±1403 vs 2559±1678 a.u. for (AUUUU)7, P=0.034).
  • It increased spontaneous tail coiling at 24 hpf (5±6 vs 3±2 coils; P=0.043 vs (AUUUU)7, P=0.003 vs vehicle) and caused late-adult motor impairment at 17 months (swimming distance 28±9 m vs 39±11 m, P=0.001; speed 9±2 vs 12±3 cm/s, P=0.0005 vs (AUUUU)7), without significant Purkinje cell differentiation defects at 120 hpf.
  • Human NOVA2 co-microinjection partially rescued PMN axon length [(AUUUC)58: 31±8 µm; (AUUUC)58+NOVA2: 37±8 µm, P=0.01]; nova2 knockdown shortened axons (24±6 µm vs vehicle 31±7 µm, P=0.00006; control MO 31±5 µm, P=0.0001), partially rescued by human NOVA2 (28±7 µm, P=0.03). RBPmap identified NOVA1 as the only database RBP with higher affinity for pathogenic RNA, with 61 predicted NOVA1 binding sites in (AUUUC)58 vs 3 in (AUUUU)199.

Methods

  • Zebrafish embryos were microinjected at the one- to two-cell stage with ~5 nl in vitro transcribed RNAs at 100 ng/µl: non-pathogenic (AUUUU)7, large non-pathogenic (AUUUU)139, pathogenic (AUUUC)58, or vehicle; GFP mRNA was co-injected to assess microinjection efficiency, and embryos were scored at 24–26 hpf and raised for later analyses.
  • Developmental and behavioral assays included survival/hatching from 0–96 hpf, morphology scoring (0–3), RT-PCR for RNA integrity, whole-mount immunofluorescence for SV2, α-bungarotoxin, and zebrin II, confocal imaging and axon tracing, spontaneous tail coiling at 24 hpf, touch-evoked escape at 72 hpf, spontaneous locomotor activity at 144 hpf, and novel diving tank tests at 3 and 17 months.
  • Mechanistic experiments used RBPmap in silico prediction, human NOVA2 mRNA co-microinjection with anti-histidine validation, and nova2 morpholino knockdown with RT-PCR validation of Nova2 target splicing (Dock6, Rap1Gap, DBS/MCF2L, Neo1); statistical analyses used ANOVA, Kruskal–Wallis, log-rank, and related post-hoc tests.

Limitations

  • Stated: the NOVA2 rescue was performed only in PMNs at 24 hpf, axon lengths did not completely return to control levels, and rescue of the adult motor phenotype was not tested.
  • Stated: zebrafish Nova2 and human NOVA2 are not functionally equivalent, as human NOVA2 did not rescue Rap1Gap, DBS (MCF2L), or Neo1 splicing defects after nova2 morpholino; the microinjection model is transient and does not cover sustained DAB1 upregulation found in patient-derived neurons.
  • Evident from the text: findings are in zebrafish using microinjected human repeat RNA, with no human fetal or patient validation; only one pathogenic repeat length (58 ATTTC) and selected non-pathogenic repeats were tested; RBP sequestration mechanisms are inferred from in silico, in vitro, and preprint data rather than directly demonstrated in this study.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1242/dmm.052636

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. SCA37-associated (AUUUC)58 RNA induces developmental defects in zebrafish. Data obtained after embryo microinjection of vehicle, (AUUUU)7, or (AUUUC)58 RNAs; seven replicates; at least 100 embryos per condition. (A) Schematic of microinjected RNAs with non-pathogenic (AUUUU)7 or pathogenic SCA37-associated (AUUUC)58 insertion, along with AluJb flanking regions. (B) Plotted survival rates of zebrafish between 0 and 96 hpf microinjected as described in A (****P<0.0001, log-rank test). (C) Plotted hatching rate of zebrafish between 0 and 96 hpf microinjected as described in A (****P<0.0001, log-rank test). (D) Representative images showing a score-0 embryo similar to wild type (left) and a score-3 embryo with severe developmental arrest (right) (scale bars: 50 µm). (E) Plot showing the percentage of scored embryos at 24 hpf. Score 0 (no morphological defects; white), score 1 (tail defects; orange), score 2 (head and tail defects; blue), score 3 (developmental arrest; red) (****P<0.0001, Kruskal–Wallis with Dunn's post-hoc test). Data are presented as the mean+standard deviation. (F) Schematic of the expected repeat length of each RNA repeat (top). Agarose gel electrophoresis, showing RT-PCR-amplified RNA repeats at the expected sizes after microinjection with vehicle, (AUUUU)7, (AUUUU)139, or (AUUUC)58 RNAs at 6 and 24 hpf (bottom).
Fig. 1. SCA37-associated (AUUUC)58 RNA induces developmental defects in zebrafish. Data obtained after embryo microinjection of vehicle, (AUUUU)7, or (AUUUC)58 RNAs; seven replicates; at least 100 embryos per condition. (A) Schematic of microinjected RNAs with non-pathogenic (AUUUU)7 or pathogenic SCA37-associated (AUUUC)58 insertion, along with AluJb flanking regions. (B) Plotted survival rates of zebrafish between 0 and 96 hpf microinjected as described in A (****P<0.0001, log-rank test). (C) Plotted hatching rate of zebrafish between 0 and 96 hpf microinjected as described in A (****P<0.0001, log-rank test). (D) Representative images showing a score-0 embryo similar to wild type (left) and a score-3 embryo with severe developmental arrest (right) (scale bars: 50 µm). (E) Plot showing the percentage of scored embryos at 24 hpf. Score 0 (no morphological defects; white), score 1 (tail defects; orange), score 2 (head and tail defects; blue), score 3 (developmental arrest; red) (****P<0.0001, Kruskal–Wallis with Dunn's post-hoc test). Data are presented as the mean+standard deviation. (F) Schematic of the expected repeat length of each RNA repeat (top). Agarose gel electrophoresis, showing RT-PCR-amplified RNA repeats at the expected sizes after microinjection with vehicle, (AUUUU)7, (AUUUU)139, or (AUUUC)58 RNAs at 6 and 24 hpf (bottom).CC BY · PubMed Central
Fig. 2. No alterations in zebrin II-positive Purkinje cell differentiation in (AUUUC)58 zebrafish larvae. (A) Schematic outlining the assessment of zebrin II-positive Purkinje cells in zebrafish larvae. One- to two-cell-stage embryos were microinjected with the non-pathogenic (AUUUU)7 RNA, pathogenic (AUUUC)58 RNAs or vehicle control, and dead or defective embryos removed at 24 hpf. Anti-zebrin II immunofluorescence was performed at 120 hpf to analyze Purkinje cells. (B) Representative z-projection images depicting zebrin II-positive Purkinje cells across conditions (scale bars: 50 µm). (C) Plot showing the volume of Purkinje cells (PCs) (one-way ANOVA). (D) Plot showing the mean intensity of Purkinje cells (Kruskal–Wallis test) as arbitrary units (a.u.). Data are presented as mean+standard deviation. Data are from three replicates including at least nine larvae per condition.
Fig. 2. No alterations in zebrin II-positive Purkinje cell differentiation in (AUUUC)58 zebrafish larvae. (A) Schematic outlining the assessment of zebrin II-positive Purkinje cells in zebrafish larvae. One- to two-cell-stage embryos were microinjected with the non-pathogenic (AUUUU)7 RNA, pathogenic (AUUUC)58 RNAs or vehicle control, and dead or defective embryos removed at 24 hpf. Anti-zebrin II immunofluorescence was performed at 120 hpf to analyze Purkinje cells. (B) Representative z-projection images depicting zebrin II-positive Purkinje cells across conditions (scale bars: 50 µm). (C) Plot showing the volume of Purkinje cells (PCs) (one-way ANOVA). (D) Plot showing the mean intensity of Purkinje cells (Kruskal–Wallis test) as arbitrary units (a.u.). Data are presented as mean+standard deviation. Data are from three replicates including at least nine larvae per condition.CC BY · PubMed Central
Fig. 3. Pathogenic (AUUUC)58 RNA induces developmental defects in PMN axons and AChR distribution in zebrafish muscle. (A) Schematic of the analyzed region in zebrafish, depicting 24-hpf primary motor neuron (PMN) axons, innervating muscle cells where acetylcholine receptors (AChRs) are localized. (B) Top: Representative z-average projections of PMNs axons in embryos microinjected with vehicle, non-pathogenic (AUUUU)7 or pathogenic (AUUUC)58 RNAs in the six-somite region anterior to the cloaca (scale bars: 50 µm). Bottom: Quantification of PMN axon lengths in the described embryos [vehicle and (AUUUU)7: n=16: (AUUUC)58: n=18; three replicates; **P<0.01 and ***P<0.001, Kruskal–Wallis with Dunn's post-hoc test]. (C) Representative z-maximum projections of neuromuscular junctions (NMJs) in the four-somite-spanning region anterior to the cloaca (scale bars: 50 µm). (D) Plot showing the AChR signal distribution along the dorsal-ventral muscle axis in the above-described embryos [vehicle and (AUUUU)7: n=19 and (AUUUC)58: n=21; three replicates; *P<0.05 and **P<0.01, one-way ANOVA with Bonferroni correction]. (E) Quantification of NMJ area [vehicle and (AUUUU)7: n=19, (AUUUC)58: n=21; three replicates; **P<0.01, one-way ANOVA with Bonferroni correction]. Data are presented as the mean+standard deviation.
Fig. 3. Pathogenic (AUUUC)58 RNA induces developmental defects in PMN axons and AChR distribution in zebrafish muscle. (A) Schematic of the analyzed region in zebrafish, depicting 24-hpf primary motor neuron (PMN) axons, innervating muscle cells where acetylcholine receptors (AChRs) are localized. (B) Top: Representative z-average projections of PMNs axons in embryos microinjected with vehicle, non-pathogenic (AUUUU)7 or pathogenic (AUUUC)58 RNAs in the six-somite region anterior to the cloaca (scale bars: 50 µm). Bottom: Quantification of PMN axon lengths in the described embryos [vehicle and (AUUUU)7: n=16: (AUUUC)58: n=18; three replicates; **P<0.01 and ***P<0.001, Kruskal–Wallis with Dunn's post-hoc test]. (C) Representative z-maximum projections of neuromuscular junctions (NMJs) in the four-somite-spanning region anterior to the cloaca (scale bars: 50 µm). (D) Plot showing the AChR signal distribution along the dorsal-ventral muscle axis in the above-described embryos [vehicle and (AUUUU)7: n=19 and (AUUUC)58: n=21; three replicates; *P<0.05 and **P<0.01, one-way ANOVA with Bonferroni correction]. (E) Quantification of NMJ area [vehicle and (AUUUU)7: n=19, (AUUUC)58: n=21; three replicates; **P<0.01, one-way ANOVA with Bonferroni correction]. Data are presented as the mean+standard deviation.CC BY · PubMed Central
Fig. 4. Decreased levels of AChR clusters in the muscle of (AUUUC)58 zebrafish larvae at 72 hpf. Neuromuscular junction (NMJ) analysis in zebrafish. (A) Representative z-maximum projections of primary motor neurons (PMNs) and acetylcholine receptors (AChRs) in larvae microinjected with vehicle, (AUUUU)7 or (AUUUC)58 RNAs (25 larvae per condition; four replicates each). Scale bars: 100 µm. (B) Quantification of AChRs in NMJs (as arbitrary units, a.u.) (*P<0.05, Kruskal–Wallis with Dunn's post-hoc test). Data are presented as the mean+standard deviation.
Fig. 4. Decreased levels of AChR clusters in the muscle of (AUUUC)58 zebrafish larvae at 72 hpf. Neuromuscular junction (NMJ) analysis in zebrafish. (A) Representative z-maximum projections of primary motor neurons (PMNs) and acetylcholine receptors (AChRs) in larvae microinjected with vehicle, (AUUUU)7 or (AUUUC)58 RNAs (25 larvae per condition; four replicates each). Scale bars: 100 µm. (B) Quantification of AChRs in NMJs (as arbitrary units, a.u.) (*P<0.05, Kruskal–Wallis with Dunn's post-hoc test). Data are presented as the mean+standard deviation.CC BY · PubMed Central
Fig. 5. (AUUUC)58-injected zebrafish exhibit hyperactive coiling behavior. (A) Schematic of involuntary tail movement of 24 hpf zebrafish embryos. (B) Number of tail coils within 60 seconds by zebrafish embryos at 24 hpf [vehicle and (AUUUU)7: n=112, (AUUUC)58: n=82; seven replicates; *P<0.05 and **P<0.01, Kruskal–Wallis with Dunn's post-hoc test]. (C) Percentage of mobile and immobile larvae during a 10-min spontaneous locomotor test at 144 hpf [vehicle: n=55, (AUUUU)7: n=58, (AUUUC)58: n=57; three replicates; χ2 test]. (D) Total swimming distance of zebrafish larvae at 144 hpf [vehicle: n=35, (AUUUU)7: n=36, (AUUUC)58: n=41; three replicates; Kruskal–Wallis test]. (E) Time spent immobile by zebrafish larvae at 144 hpf [vehicle: n=35, (AUUUU)7: n=36, (AUUUC)58: n=41; three replicates; Kruskal–Wallis test]. (F) Number of immobility episodes in larvae at 144 hpf, i.e. immobile for ≥2 s [vehicle: n=35, (AUUUU)7: n=36, (AUUUC)58: n=41; three replicates; *P<0.05, Kruskal–Wallis with Dunn's post-hoc test). Data are presented as the mean+standard deviation.
Fig. 5. (AUUUC)58-injected zebrafish exhibit hyperactive coiling behavior. (A) Schematic of involuntary tail movement of 24 hpf zebrafish embryos. (B) Number of tail coils within 60 seconds by zebrafish embryos at 24 hpf [vehicle and (AUUUU)7: n=112, (AUUUC)58: n=82; seven replicates; *P<0.05 and **P<0.01, Kruskal–Wallis with Dunn's post-hoc test]. (C) Percentage of mobile and immobile larvae during a 10-min spontaneous locomotor test at 144 hpf [vehicle: n=55, (AUUUU)7: n=58, (AUUUC)58: n=57; three replicates; χ2 test]. (D) Total swimming distance of zebrafish larvae at 144 hpf [vehicle: n=35, (AUUUU)7: n=36, (AUUUC)58: n=41; three replicates; Kruskal–Wallis test]. (E) Time spent immobile by zebrafish larvae at 144 hpf [vehicle: n=35, (AUUUU)7: n=36, (AUUUC)58: n=41; three replicates; Kruskal–Wallis test]. (F) Number of immobility episodes in larvae at 144 hpf, i.e. immobile for ≥2 s [vehicle: n=35, (AUUUU)7: n=36, (AUUUC)58: n=41; three replicates; *P<0.05, Kruskal–Wallis with Dunn's post-hoc test). Data are presented as the mean+standard deviation.CC BY · PubMed Central
Fig. 6. Pathogenic (AUUUC)58 causes motor impairment in late-adult zebrafish at 17 months and negatively affects motor performance in fish aged 3 to 17 months. (A-C) Novel diving tank test conducted on microinjected animals at 17 months [vehicle and (AUUUU)7: n=20, (AUUUC)58: n=19]. Percentage of immobile animals (Kruskal–Wallis test) (A). Total swimming distance (*P<0.05 and **P<0.01, two-way ANOVA with condition and sex as factors) (B). Average swimming speed (*P<0.05 and ***P<0.001, two-way ANOVA with condition and sex as factors) (C). (D-F) Novel diving tank test performed with animals aged 3 months (n=14 animals per condition) and 17 months [vehicle and (AUUUU)7: n=20, (AUUUC)58: n=19]. Percentage of immobile animals (Mann–Whitney U-test) (D). Total swimming distance (**P<0.01 and ****P<0.0001, two-way ANOVA with condition and age as factors) (E). Average swimming speed while animals are active (***P<0.001 and ****P<0.0001, two-way ANOVA with condition and age as factors) (F). Data are shown as the mean+standard deviation.
Fig. 6. Pathogenic (AUUUC)58 causes motor impairment in late-adult zebrafish at 17 months and negatively affects motor performance in fish aged 3 to 17 months. (A-C) Novel diving tank test conducted on microinjected animals at 17 months [vehicle and (AUUUU)7: n=20, (AUUUC)58: n=19]. Percentage of immobile animals (Kruskal–Wallis test) (A). Total swimming distance (*P<0.05 and **P<0.01, two-way ANOVA with condition and sex as factors) (B). Average swimming speed (*P<0.05 and ***P<0.001, two-way ANOVA with condition and sex as factors) (C). (D-F) Novel diving tank test performed with animals aged 3 months (n=14 animals per condition) and 17 months [vehicle and (AUUUU)7: n=20, (AUUUC)58: n=19]. Percentage of immobile animals (Mann–Whitney U-test) (D). Total swimming distance (**P<0.01 and ****P<0.0001, two-way ANOVA with condition and age as factors) (E). Average swimming speed while animals are active (***P<0.001 and ****P<0.0001, two-way ANOVA with condition and age as factors) (F). Data are shown as the mean+standard deviation.CC BY · PubMed Central
Fig. 7. NOVA2 mitigates axonal defects caused by pathogenic (AUUUC)58 RNA in zebrafish PMNs. (A) Maximum z-scores of putative RNA-binding proteins (RBPs) that bind non-pathogenic (AUUUU)199 or pathogenic (AUUUC)58 RNA, assessed by using the RBPmap tool (P<0.05). (B) Average z-score for each binding site for NOVA1 within (AUUUU)199 or (AUUUC)58 RNA. Data are shown as the mean+standard deviation. (C) Representative z-average projections of zebrafish primary motor neuron (PMN) axons in the six-somite region anterior to the cloaca at 24 hpf (scale bars: 50 µm). (D) Length of PMN axons in embryos microinjected with either vehicle, NOVA2 (NOVA2), (AUUUU)7, (AUUUC)58, or a combination of (AUUUC)58 and NOVA2 [(AUUUC)58 +NOVA2] mRNA (n=30 embryos per condition; three replicates; *P<0.05, ***P<0.001 and ****P<0.0001, two-way ANOVA with conditions and replicates as factors, followed by Bonferroni post-hoc test for axon length, after applying a cube root data transformation). Raw data are represented as the mean+standard deviation. (E) Z-projection images showing the nuclear and cytoplasmic distribution of human NOVA2 in 24 hpf zebrafish muscle after NOVA2 mRNA microinjection. Representative z-maximum projections with (left) and without (right) anti-histidine primary antibody (white). Nuclei were stained with DAPI (purple). Scale bars: 5 µm.
Fig. 7. NOVA2 mitigates axonal defects caused by pathogenic (AUUUC)58 RNA in zebrafish PMNs. (A) Maximum z-scores of putative RNA-binding proteins (RBPs) that bind non-pathogenic (AUUUU)199 or pathogenic (AUUUC)58 RNA, assessed by using the RBPmap tool (P<0.05). (B) Average z-score for each binding site for NOVA1 within (AUUUU)199 or (AUUUC)58 RNA. Data are shown as the mean+standard deviation. (C) Representative z-average projections of zebrafish primary motor neuron (PMN) axons in the six-somite region anterior to the cloaca at 24 hpf (scale bars: 50 µm). (D) Length of PMN axons in embryos microinjected with either vehicle, NOVA2 (NOVA2), (AUUUU)7, (AUUUC)58, or a combination of (AUUUC)58 and NOVA2 [(AUUUC)58 +NOVA2] mRNA (n=30 embryos per condition; three replicates; *P<0.05, ***P<0.001 and ****P<0.0001, two-way ANOVA with conditions and replicates as factors, followed by Bonferroni post-hoc test for axon length, after applying a cube root data transformation). Raw data are represented as the mean+standard deviation. (E) Z-projection images showing the nuclear and cytoplasmic distribution of human NOVA2 in 24 hpf zebrafish muscle after NOVA2 mRNA microinjection. Representative z-maximum projections with (left) and without (right) anti-histidine primary antibody (white). Nuclei were stained with DAPI (purple). Scale bars: 5 µm.CC BY · PubMed Central
Fig. 8. Nova2 knockdown in zebrafish induces PMN axonopathy, recapitulating the (AUUUC)58 RNA microinjection effect. (A) Top: Percentage of inclusion of exon 23 and 24 in Dock6 at 24 hpf after microinjection of control (Control MO) or nova2 morpholino (nova2 MO), or co-microinjection of nova2 morpholino and human NOVA2 mRNA (nova2 MO +NOVA2; (*P<0.05, one-way ANOVA with Welch correction and Dunnett's T3 post-hoc test; three biological replicates). Data are represented as mean+standard deviation. Bottom: Schematic of inclusion of alternatively spliced exons 23 and 24 in Dock6 transcripts, along with the corresponding Bioanalyzer electrophoresis. (B) Representative z-average projections of primary motor neuron (PMN) axons in the six-somite region anterior to the cloaca in zebrafish at 24 hpf (scale bars: 50 µm). (C) Quantification of PMN axon length in embryos microinjected with vehicle, standard control morpholino (Control MO), nova2 morpholino (nova2 MO), or a combination of nova2 morpholino and human NOVA2 (nova2 MO +NOVA2) mRNA (n=32 embryos per condition; three replicates; *P<0.05, ***P<0.001 and ****P<0.0001, one-way ANOVA with Bonferroni post-hoc test). Data are represented as the mean+standard deviation. (D) Hypothetical model describing (AUUUC)58-driven SCA37 neurodevelopmental axonopathy in zebrafish. Left: During development, DAB1 comprising the non-pathogenic repeat is expressed in motor neurons, allowing neuromuscular junction (NMJ) formation via axonal growth towards pre-patterned clusters of acetylcholine receptor (AChR). In these neurons, NOVA2 regulates the alternative splicing of axon pathfinding-related transcripts (e.g. neuron-specific Z+ agrin protein isoforms are released along muscle tissue, stabilizing AChR clusters). Right: In SCA37 motor neurons, DAB1 comprising the pathogenic ATTTC repeat might form (AUUUC)58 RNA aggregates, sequestering RNA-binding proteins (RBPs) like NOVA2. This NOVA2 loss-of-function might lead to aberrant splicing in PMNs, resulting in axonal shortening and abnormal AChR clustering/positioning near the horizontal myoseptum.
Fig. 8. Nova2 knockdown in zebrafish induces PMN axonopathy, recapitulating the (AUUUC)58 RNA microinjection effect. (A) Top: Percentage of inclusion of exon 23 and 24 in Dock6 at 24 hpf after microinjection of control (Control MO) or nova2 morpholino (nova2 MO), or co-microinjection of nova2 morpholino and human NOVA2 mRNA (nova2 MO +NOVA2; (*P<0.05, one-way ANOVA with Welch correction and Dunnett's T3 post-hoc test; three biological replicates). Data are represented as mean+standard deviation. Bottom: Schematic of inclusion of alternatively spliced exons 23 and 24 in Dock6 transcripts, along with the corresponding Bioanalyzer electrophoresis. (B) Representative z-average projections of primary motor neuron (PMN) axons in the six-somite region anterior to the cloaca in zebrafish at 24 hpf (scale bars: 50 µm). (C) Quantification of PMN axon length in embryos microinjected with vehicle, standard control morpholino (Control MO), nova2 morpholino (nova2 MO), or a combination of nova2 morpholino and human NOVA2 (nova2 MO +NOVA2) mRNA (n=32 embryos per condition; three replicates; *P<0.05, ***P<0.001 and ****P<0.0001, one-way ANOVA with Bonferroni post-hoc test). Data are represented as the mean+standard deviation. (D) Hypothetical model describing (AUUUC)58-driven SCA37 neurodevelopmental axonopathy in zebrafish. Left: During development, DAB1 comprising the non-pathogenic repeat is expressed in motor neurons, allowing neuromuscular junction (NMJ) formation via axonal growth towards pre-patterned clusters of acetylcholine receptor (AChR). In these neurons, NOVA2 regulates the alternative splicing of axon pathfinding-related transcripts (e.g. neuron-specific Z+ agrin protein isoforms are released along muscle tissue, stabilizing AChR clusters). Right: In SCA37 motor neurons, DAB1 comprising the pathogenic ATTTC repeat might form (AUUUC)58 RNA aggregates, sequestering RNA-binding proteins (RBPs) like NOVA2. This NOVA2 loss-of-function might lead to aberrant splicing in PMNs, resulting in axonal shortening and abnormal AChR clustering/positioning near the horizontal myoseptum.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 73 Not checked · 119 Own results and interpretations

90 more claims

Create a free account to see all 192 claims and to verify the 102 references still open.

See all claims — free account
  • The quote only partly states this claim. 3
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 57

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 74 references

Cited by

Metadata

Authors
Castro, A. F., Figueiredo, A. S., Loureiro, J. R., Azevedo, M. M., Sampaio, P., Valentim, A. M., Bessa, J., & Silveira, I.
Affiliations
Universidade do Porto (PT)
Corresponding author
Silveira, Isabel
Venue
Disease Models & Mechanisms
Published
2026-04-01
Volume
19
Issue
4
ISSN
  • 1754-8403 (ISSN-L)
  • 1754-8411
OpenAlex
W7138846058
Cited by
3
References
74
Citations by year
2026: 2
FWCI
2.47
Type
journal article
Language
en
Open access
Locations
  • Disease Models & Mechanisms (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Fundação para a Ciência e a Tecnologia
  • the European Regional Development Fund; COMPETE2030 and Fundação para a Ciência e a Tecnologia
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
Dab1, neurodevelopmental defects, axon growth, motor neuron innervation, muscle innervation, motor impairment, NOVA2, splicing regulation, zebrafish model, neurodegeneration
MeSH terms
Neuro-Oncological Ventral Antigen, Neurodevelopment, Animals, Axons, Disease Models, Animal, Embryo, Nonmammalian, Motor Activity, Motor Neurons, Muscles, Nerve Tissue Proteins, Phenotype, RNA, Synapses, Zebrafish, RNA-Binding Proteins, Spinocerebellar Ataxias, Zebrafish Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.